Trademark: 79188650
Word
ANEMOCYTE
Status
Registered
Status Code
700
Status Date
Tuesday, June 6, 2017
Serial Number
79188650
Registration Number
5215720
Registration Date
Tuesday, June 6, 2017
Mark Type
4
Filing Date
Friday, September 11, 2015
Published for Opposition
Tuesday, March 21, 2017

Trademark Owner History
ANEMOCYTE S.R.L. - Original Registrant
ARETA INTERNATIONAL S.R.L. - Owner At Publication

Classifications
5 Pharmaceutical and veterinary preparations, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for use in human and veterinary medicine; chemical preparations for pharmaceutical or medical purposes, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets, syringes, infusion bags, vials and pharmaceutical preparations for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; biological preparations for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; biological preparations for medical and pharmaceutical use for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; chemical preparations for pharmaceutical purposes, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; preparations for diagnostics for medical purposes; drugs, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for medical and veterinary purposes; medicines for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; organic products for medical use, namely, natural biomaterials for cell delivery or for augmentation of tissues for medical purposes; biological reagents for medical use; medicinal products based on cells and genes, namely, somatic cells, genetically modified cells, viral vectors, nucleic acids and engineered tissues; products for somatic cell therapy, namely, adult stem cells, t-cells, b-cells, nk cells, dendritic cells, monocytes, macrophages, adipocytes, keratinocytes, erythrocytes, platelets, products for gene therapy, namely, genetically modified cells, viral vectors, nucleic acids; tissue engineered products, namely, cells and tissues that have been subjected to extensive manipulation and are used with the aim to repair, replace or restore a lost or impaired tissue or function; products for regenerative medicine, namely, cells and tissues that have been subjected to extensive manipulation and are used with the aim to repair, replace, restore or promote the repair, replacement or regeneration of a lost or impaired tissue or function; products for personalized medicine made of autologous cells or proteins or nucleid acids derived from individual genomic sequences; preparations made up of cells for medical or clinical use; preparations made up of nucleic acids, namely, nucleic acid sequences and chemical reagents for medical purposes; preparations made up of tissues, namely, biological tissue cultures for medical purposes; vaccines; recombinant proteins supplements; therapeutic kits consisting of therapeutic antibodies, buffers, and reagents for use in disease treatment and therapy
10 [ Surgical apparatus and instruments for medical, dental and veterinary use; medical devices for the introduction of pharmaceutical preparations in the human body, in particular syringes and catheters; medical equipment, namely, centrifuges or other separation devices for the isolation of cell sub-populations from tissues and biopsies; surgical apparatus and instruments for medical and veterinary purpose; electrical medical instruments for use in electroporation of cells and tissues for gene transfer purposes, both in vivo and ex-vivo; electronic medical instruments for use in imaging for diagnostic purposes or for monitoring of vital signs of patients ]
42 Services of laboratory analysis and industrial research in the medical and pharmaceutical fields; research and development in the pharmaceutical and biotechnology fields; research and development in the field of micro-organisms and cells; research and development in biochemistry; scientific research and development in biology; research and development in the field of diagnostic preparations; services of medical laboratories; Providing medical and scientific research information and data on developments in the medical and veterinary fields; scientific and technological services, namely, scientific research in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; consultancy to ensure compliance with quality standards and the design and validation of manufacturing processes in the scientific field and medical technology fields

Trademark Events
Jul 12, 2016
Application Filing Receipt Mailed
Jul 7, 2016
Sn Assigned For Sect 66a Appl From Ib
Jul 8, 2016
New Application Office Supplied Data Entered
Jul 8, 2016
Assigned To Examiner
Jul 11, 2016
Non-Final Action Written
Jul 12, 2016
Non-Final Action (Ib Refusal) Prepared For Review
Jul 13, 2016
Refusal Processed By Mpu
Jul 13, 2016
Non-Final Action Mailed - Refusal Sent To Ib
Jul 29, 2016
Refusal Processed By Ib
Oct 11, 2016
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Oct 11, 2016
Attorney/Dom.Rep.Revoked And/Or Appointed
Nov 16, 2016
Teas Response To Office Action Received
Dec 7, 2016
Assigned To Lie
Dec 22, 2016
Correspondence Received In Law Office
Dec 22, 2016
Teas/Email Correspondence Entered
Jan 8, 2017
Final Refusal Written
Jan 8, 2017
Final Refusal E-Mailed
Jan 8, 2017
Notification Of Final Refusal Emailed
Feb 1, 2017
Examiners Amendment -Written
Feb 1, 2017
Examiners Amendment E-Mailed
Feb 1, 2017
Notification Of Examiners Amendment E-Mailed
Feb 1, 2017
Examiner's Amendment Entered
Feb 1, 2017
Examiners Amendment -Written
Feb 1, 2017
Examiners Amendment E-Mailed
Feb 1, 2017
Notification Of Examiners Amendment E-Mailed
Feb 1, 2017
Examiner's Amendment Entered
Feb 1, 2017
Approved For Pub - Principal Register
Feb 14, 2017
Law Office Publication Review Completed
Mar 1, 2017
Notification Of Notice Of Publication E-Mailed
Mar 1, 2017
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Mar 1, 2017
Notification Of Possible Opposition Sent To Ib
Mar 17, 2017
Notification Processed By Ib
Mar 21, 2017
Published For Opposition
Mar 21, 2017
Official Gazette Publication Confirmation E-Mailed
Jun 6, 2017
Registered-Principal Register
Sep 6, 2017
Final Disposition Notice Created, To Be Sent To Ib
Sep 14, 2017
Final Disposition Processed
Sep 14, 2017
Final Disposition Notice Sent To Ib
Oct 28, 2017
Final Decision Transaction Processed By Ib
Feb 22, 2018
Change Of Name/Address Rec'd From Ib
Apr 9, 2021
New Representative At Ib Received
Jun 6, 2022
Courtesy Reminder - Sec. 71 (6-Yr) E-Mailed
Oct 24, 2022
Teas Change Of Owner Address Received
Oct 24, 2022
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Oct 24, 2022
Attorney/Dom.Rep.Revoked And/Or Appointed
Oct 24, 2022
Teas Withdrawal Of Attorney Received-Firm Retains
Oct 24, 2022
Teas Change Of Domestic Representatives Address
Oct 24, 2022
Teas Change Of Correspondence Received
Oct 24, 2022
Applicant/Correspondence Changes (Non-Responsive) Entered
Jun 5, 2023
Teas Section 71 Received
Feb 12, 2024
Case Assigned To Post Registration Paralegal
Feb 24, 2024
Post Registration Action Mailed - Sec.71
Aug 21, 2024
Teas Response To Office Action-Post Reg Received

Trademark Alertz updated from USPTO on 2030-01-24